Portfolio — 2 April 2026

The Trump Administration's imposition of a 100 per cent tariff on pharmaceutical exports — effective immediately and striking Australian exporters who ship roughly $1.6 billion worth of product to the US annually — placed the Minister for Disability and the National Disability Insurance Scheme, Minister for Health and Ageing and Deputy Leader of the House, Mr Butler, at the centre of Australia's trade-and-health policy response on 2 April [TA-260403-health-bc4f9b62cbf5].

The minister's most consequential move was to draw a hard line around the Pharmaceutical Benefits Scheme: he stated publicly that domestic medicine prices will not be affected and that the PBS is protected by Australian law and will not be negotiated under any circumstances [TA-260403-health-002934c422f1]. That formulation forecloses any reading of the tariff dispute as leverage over Australian medicine pricing and is the clearest policy signal the minister has put on the record.

On the exporter exposure question, the minister differentiated between segments of the Australian pharmaceutical industry [TA-260403-health-002934c422f1]. CSL, Australia's largest pharmaceutical exporter, holds substantial manufacturing operations in the United States and is expected to be materially insulated from the tariff through the current year. Smaller Australian manufacturers with US market exposure face a different outlook, and the records flag significant concern for that cohort.

The government committed to engaging both the US Administration and Australian exporters to clarify the tariff's scope — framing the measure as the latest in a series of US trade actions over the past twelve months rather than an isolated event [TA-260403-health-bc4f9b62cbf5].

The portfolio's stated approach is two-tracked: treat the PBS as non-negotiable in any trade forum, while simultaneously pressing the US Administration to reverse the tariff on the basis that the Australia–US free trade relationship has operated for over two decades to mutual benefit. The minister also described the tariff as an act inconsistent with the conduct expected of a close ally — a framing with Foreign Affairs dimensions that extends beyond the Health portfolio's immediate remit.

Notably, the Opposition Leader endorsed the government's position on PBS protection and called for exemptions for Australian exporters, characterising the issue as requiring cross-party effort to secure tariff relief. That degree of bipartisan alignment on the PBS non-negotiation commitment narrows the domestic political contest to questions of diplomatic strategy and exporter support, rather than the principle itself.

No parliamentary sitting-day record is present in this window; the activity captured here is drawn solely from ministerial media releases.